Medical adhesive for bone trauma repair and preparation method thereof

Through amidated castor oil polyol and dopamine grafting, combined with thioketal and ethylene glycol, the problem of uncontrollable adhesion and degradation properties of medical bone adhesives is solved, and effective adhesion and controllable degradation in bone trauma repair is achieved. , enhances the clinical application value of adhesives.

CN118903527APending Publication Date: 2024-11-08SHANGHAI JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411097115.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing medical bone adhesives have poor wet adhesion performance and uncontrollable biodegradation performance, resulting in failure of adhesion or hindering the generation of new bones, limiting their application.

Method used

By amidating castor oil polyol and grafting dopamine, combining thioketal and ethylene glycol structural units, the degradation site density and hydrophilicity of medical adhesives are regulated, and the adhesion performance and degradation time are controlled.

Benefits of technology

It has obtained a medical adhesive that is easy to operate and controllable degradation, with good wet adhesion ability and rapid curing performance, which is suitable for bone trauma repair and promotes bone healing and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903527A_ABST
    Figure CN118903527A_ABST
Patent Text Reader

Abstract

The invention provides a medical adhesive for bone trauma repair and a preparation method thereof, the medical adhesive comprises a component A and a component B, the component A is an isocyanate terminated polyurethane prepolymer, and the component B comprises dopamine modified castor oil polyol, inorganic particles, a catalyst and a foaming agent. The bonding system has injectable performance, can adapt to various wound shapes, and can realize rapid curing after uniform injection and mixing, and the cured adhesive can effectively fix a fracture part. Furthermore, a main chain containing a thioketal group in the medical adhesive is broken under the attack of active oxygen to generate an acetone and sulfydryl residue compound, so that an active oxygen degradation behavior is shown, in addition, more ethylene glycol structural units can improve the hydrophilicity of a material and assist the degradation of the medical adhesive, so that the medical adhesive has a good application prospect. Therefore, the purpose of regulating and controlling the degradation time of the medical adhesive can be achieved by controlling the proportion of the thioketal group and the ethylene glycol structural unit in the main chain.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical materials, and in particular to a medical adhesive for repairing bone trauma and a preparation method thereof. Background Art

[0002] Medical bone adhesives are a type of biomedical material that can be directly applied to the human body. They can be used to attach tiny bone fragments and artificial implants to living bones, or to repair and reconstruct small areas of bones. Compared with traditional external fixation or metal internal fixation surgeries, medical bone adhesives not only have the advantages of easy operation and strong applicability, but also do not require drilling holes in the bones, significantly reducing the risk of secondary damage to fragile bones.

[0003] Currently, commonly used medical bone adhesives can be divided into two categories: natural and synthetic. Natural bone adhesives have excellent biocompatibility and biodegradability, but the bonding strength is often difficult to meet clinical requirements. Currently developed commercial bone adhesives are mostly synthetic bone adhesives, such as polycyanoacrylates and polymethyl methacrylates, which have been used in clinical practice. However, the medical bone adhesives currently produced generally have problems such as poor wet adhesion and uncontrollable biodegradability. For example, when the degradation degree of existing biological tissue adhesives in the human body is uncontrollable, too fast degradation will cause bonding failure, and too slow degradation will hinder new bone formation, limiting the further application of this type of biological tissue adhesive.

[0004] Therefore, in response to the above problems, technicians in this field need to fully consider the actual situation of the medical use environment and design a medical adhesive for bone trauma repair from the perspective of molecular design, so as to effectively fix the fracture while controlling the degradation rate of the medical adhesive to match the bone healing rate. Summary of the invention

[0005] In order to solve the problems of poor wet adhesion and uncontrollable biodegradability of existing medical bone adhesives, the present invention provides a medical adhesive for bone trauma repair and a preparation method thereof. Castor oil polyol (or modified castor oil polyol) is amidated and grafted with dopamine, and the dopamine grafting rate is high, so that the obtained medical bone adhesive has good adhesion performance. At the same time, the ratio of the introduced thioketal group and the ethylene glycol structural unit is controlled to regulate the degradation site density and hydrophilicity of the medical adhesive, thereby regulating the degradation time of the medical adhesive.

[0006] In a first aspect, the present invention provides a medical adhesive for bone trauma repair, comprising component A and component B, wherein component A is an isocyanate-terminated polyurethane prepolymer, and component B comprises dopamine-modified castor oil polyol, inorganic particles, a catalyst and a foaming agent, wherein the molar ratio of -NCO groups in the isocyanate-terminated polyurethane prepolymer to -OH groups in the dopamine-modified castor oil polyol is (0.8-1.2):1, wherein the preferred molar ratio is (0.95-1.1):1, and the more preferred molar ratio is (1-1.05):1.

[0007] Furthermore, the organic component of the medical adhesive contains two groups that can promote degradation in the body: thioketal (or thioketal) and ethylene glycol. By adjusting the molar ratio of thioketal (or thioketal) and ethylene glycol in the medical adhesive to 1: (0 to 3), preferably 1: (0.1 to 2), the degradation time of the medical adhesive can be controlled to range from several weeks to several months.

[0008] In some embodiments, the isocyanate-terminated polyurethane prepolymer (component A) is prepared by the following method:

[0009] The first step: firstly, the ketal compound M reacts with the thiol compound N to generate the sulfur-containing ketal monomer O;

[0010] Step 2: The halogenated alcohol is reacted with the sulfur-containing ketal monomer O to obtain the polythioketal polyol P;

[0011] Step 3: Finally, the isocyanate-terminated polyurethane prepolymer is obtained by reacting the polythioacetal polyol P with the isocyanate-containing compound U, wherein the molar ratio (R value) of the -NCO group in the isocyanate-containing compound U to the -OH group in the polythioacetal polyol P is (0.8-1.2):1.

[0012] Wherein, the ketal compound M refers to a compound containing The compound of structure, for example, 2,2-dimethoxypropane; the thiol compound N refers to a compound having the general formula: Preferably, the thiol compound N is selected from 3,6-dioxa-1,8-octanedithiol (EG2), bis(2-mercaptoethyl) ether (EG1) and 1,4-butanedithiol (EG0); preferably, the molar ratio of the ketal compound M to the thiol compound N is in the range of (1-2):1, and the smaller the molar ratio, the higher the degree of polymerization of the obtained polythioketal polyol P, the higher the molecular weight, and the shorter the degradation time of the medical adhesive.

[0013] The sulfur ketal monomer O refers to A compound of the structure, wherein R1, R2, R3 and R4 are alkanes.

[0014] The polythioketal polyol P refers to a polyol having the general formula: A compound wherein x is an integer of 1-20, preferably 1-5; for example, the polythioketal polyol P may be a polythioketal diol, including EG0 PTK diol, EG1 PTK diol and EG2 PTK diol.

[0015] The isocyanate-containing compound U is selected from diisocyanates and polyisocyanates, and the diisocyanates include one or more of diphenylmethane diisocyanate, toluene diisocyanate, p-phenylene diisocyanate, m-xylylene diisocyanate, tetramethylm-xylylene diisocyanate, dimethylbiphenyl diisocyanate, and dimethyldiphenylmethane diisocyanate; the polyisocyanate refers to an isocyanate compound containing three or more -NCO groups, selected from one or more of polymethylene polyphenyl polyisocyanate, triphenylmethane triisocyanate, and dimethyltriphenylmethane tetraisocyanate. The present invention finds that when the isocyanate-containing compound is a hydrogenated aromatic isocyanate composition containing two or more -NCO groups, the bonding effect of the obtained medical adhesive for bone trauma repair is better.

[0016] In some embodiments, the B component is prepared by the following method:

[0017] The first step: firstly grafting succinic anhydride onto castor oil, castor oil polyol or modified castor oil polyol through condensation reaction;

[0018] Step 2: preparing dopamine-modified castor oil polyol through amidation reaction with dopamine;

[0019] Step 3: Mixing the dopamine-modified castor oil polyol with inorganic particles, a catalyst and a foaming agent to obtain component B.

[0020] In some embodiments, the molecule of component A contains Structure, wherein n is any integer from 1 to 100. Component B contains polyethylene glycol, and its number average molecular weight ranges from 100 to 10,000, preferably from 500 to 5,000, and most preferably from 800 to 2,500.

[0021] In some embodiments, the catalyst is an amine catalyst, preferably an amine catalyst that is non-toxic or low-toxic to the human body, more preferably one or more of 1,2-dimethylimidazole, triethylenediamine, pentamethyldiethylenetriamine, pentamethyldipropylenetriamine, etc., and the mass fraction of the catalyst in component B is 0.05% to 0.2%.

[0022] In some embodiments, the foaming agent is water, and the mass fraction of the foaming agent in the component B is 0.05% to 0.1%.

[0023] In some embodiments, the inorganic particles are one or more of α-tricalcium phosphate, β-tricalcium phosphate, calcium carbonate, hydroxyapatite, and biphasic calcium phosphate, which can be hydrolyzed or enzymatically hydrolyzed in vivo to form ionic compounds. The mass fraction of the inorganic particles in component B is 5% to 20%. Inorganic particles suitable for bone growth are preferably used, and the composition is close to that of natural bones. Adding inorganic components to bone adhesive materials can not only improve the strength of the material, but also prepare a structure close to the bone in the human body, which is more conducive to the growth and regeneration of broken bones.

[0024] In some embodiments, the isocyanate-terminated polyurethane prepolymer, the dopamine-modified castor oil polyol, the inorganic particles, the catalyst and the blowing agent are mixed into a homogeneous system to obtain a shapeable mixture, the shape of which can be adjusted and fixed within 5-30 minutes.

[0025] In a second aspect, the present invention provides a method for preparing the above-mentioned medical adhesive for bone trauma repair, comprising mixing component A and component B according to the functional group molar ratio -NCO:-OH=(0.8~1.2):1 through a mixing syringe, wherein the mixing syringe is composed of a spiral mixing nozzle needle, a cavity, an inner tube and a push rod, and the cavity is divided into two independent cavities. When in use, the inner tube is installed in the cavity, and the A and B components are divided into the two inner tubes. When the push rod is pushed, the A and B components enter the spiral mixing nozzle needle, are mixed and pushed out, and the medical adhesive is obtained.

[0026] When using, apply the medical adhesive for bone trauma repair to the bone trauma surface to be bonded, keep it for 30 seconds to 5 minutes, put the broken bone fragments back in their original physiological shape, press lightly and wait for the adhesive to solidify before suturing the wound.

[0027] Technical Effects

[0028] The present invention can provide a medical adhesive for bone trauma repair that is easy to operate, can promote the healing of bone trauma, has good wet adhesion and controllable degradation capabilities, plays a role in maintaining bone stability and promoting wound healing, and has clinical application value.

[0029] The adhesive system of the present invention has injectable properties, can adapt to various wound shapes, has a wide range of applications, and can achieve rapid solidification after injection and mixing, and the solidified adhesive can effectively fix fractures.

[0030] In addition, the main chain containing thioketal groups in medical adhesives breaks under the attack of active oxygen, generating acetone and thiol residue compounds, showing active oxygen degradation behavior.

[0031] In addition, more ethylene glycol structural units can improve the hydrophilicity of the material and assist the degradation of medical adhesives.

[0032] The purpose of regulating the degradation time of the medical adhesive can be achieved by controlling the ratio of the thioketal group and the ethylene glycol structural unit in the main chain. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The synthetic routes of the three polythioketal diols synthesized in Examples 1, 4 and 5 are as follows;

[0034] Figure 2 1 is the H-NMR spectra of the three polythioketal diols synthesized in Examples 1, 4 and 5;

[0035] Figure 3 The following is the synthetic route of dopamine-modified castor oil used in Examples 1-8. DETAILED DESCRIPTION

[0036] The following introduces several preferred embodiments of the present invention to make its technical content clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.

[0037] Example 1

[0038] Preparation of component A:

[0039] 1. Preparation of polythioketal dithiols

[0040] Under nitrogen protection, 300 ml of anhydrous acetonitrile, 36.46 g of 3,6-dioxa-1,8-octanedithiol (EG2), and 0.19 g of p-toluenesulfonic acid were stirred evenly, heated to reflux, and then 17.36 g of 2,2-dimethoxypropane was added dropwise to the reactor. After the addition was completed, the reaction was continued for 16 hours. The solvent was removed by rotary evaporation, and p-toluenesulfonic acid was filtered out, and then precipitated in cold ethanol three times and vacuum dried to obtain a double-terminated thiol polythioketal dithiol.

[0041] 2. Preparation of polythioketal diol

[0042] 30 g of the polythioketal dithiol prepared in the previous step was added to the reactor, and then 300 mL of tetrahydrofuran, 30 g of cesium carbonate and 15 g of 2-bromoethanol were added and stirred evenly. The mixture was reacted at room temperature for 12 hours, and the cesium carbonate was removed by filtration. After the solvent was removed by rotary evaporation, the mixture was precipitated in cold ethanol for 3 times and dried to obtain the polythioketal diol. Subsequently, the hydroxyl value of the obtained polythioketal diol was measured according to the national standard GB / T12008.3-2009 to be 52 mg KOH / g.

[0043] 3. Preparation of polyurethane prepolymer

[0044] According to R value = 3 (R value is the molar ratio of isocyanate group (-NCO) to hydroxyl group (-OH) in polyurethane), 28.5 g of polythioacetal diol prepared in the second step was added to the reactor and the water was thoroughly removed. Under nitrogen protection, 1 g of polymethylene polyphenyl polyisocyanate and 9 g of diphenylmethane diisocyanate were added. The reaction was heated at 80° C. under nitrogen protection for prepolymerization for 5 hours to obtain a polyurethane prepolymer, which was then dried and sealed at low temperature for storage.

[0045] Preparation of component B

[0046] 4. 100 g of modified castor oil polyol T400 and 23.8 g of succinic anhydride were added to the reactor and heated to 125 ° C to completely melt the succinic anhydride. Subsequently, 10 mL of 2-butanone and 0.124 g of 4-dimethylaminopyridine were added and reacted at 120 ° C for 6 h. After the reaction was completed, the temperature was lowered to 90 ° C, and 10 mL of water was added to react for 30 min. After the reaction solution was cooled to room temperature, it was repeatedly washed with water until the pH value of the washing solution was close to 7. The water was removed from the mixture by rotary evaporation to obtain an intermediate.

[0047] Dissolve 30g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide and 30g of N-hydroxysuccinimide in 75mL of anhydrous ethanol, and add them to the reactor together with 50g of the above intermediate. Adjust the pH value to 5 with HCl-ethanol solution. Dissolve 28.4g of dopamine hydrochloride in 75mL of DMF, add it to the above solution, and then adjust the pH value to 8 with triethylamine. React for 12h in the dark at room temperature under nitrogen protection. Wash the product once with dilute hydrochloric acid and twice with saturated salt. Extract with ethyl acetate, filter, concentrate by rotary evaporation, and dry in vacuo to obtain dopamine-modified castor oil. The synthetic route of dopamine-modified castor oil is as follows: Figure 3 shown.

[0048] Subsequently, 10% by mass of hydroxyapatite as an inorganic particle filler was added to the dopamine-modified castor oil, and 0.03% by mass of water as a foaming agent and 0.1% by mass of triethylenediamine solution as a catalyst were added and mixed evenly to obtain component B.

[0049] Preparation of medical adhesives

[0050] 5. When in use, components A and B are mixed through a mixing syringe according to the functional group molar ratio of -NCO:-OH=1.05:1. The mixing syringe consists of a spiral mixing nozzle needle, a cavity, an inner tube and a push rod. The cavity is divided into two independent cavities. When in use, the inner tube is installed in the cavity, and components A and B are separately installed in the two inner tubes. When the push rod is pushed, components A and B enter the spiral mixing nozzle needle, mix and are pushed out, and the medical adhesive can be obtained.

[0051] Embodiment 2:

[0052] The steps are similar to those of Example 1, except that in the preparation of polythioketal dithiol in step 1, the amount of 2,2-dimethoxypropane added is changed to 15.6 g; in the preparation of polythioketal diol in step 2, the amount of 2-bromoethanol is changed to 18 g, and the measured hydroxyl value is changed to 70 mg KOH / g; in the preparation of polythioketal diol in step 3, the amount of polythioketal diol is changed to 21.19 g.

[0053] Embodiment 3:

[0054] The steps are similar to those of Example 1, except that in the preparation of polythioketal dithiol in step 1, the amount of 2,2-dimethoxypropane added is changed to 10.4 g; in the preparation of polythioketal diol in step 2, the amount of 2-bromoethanol is changed to 20 g, and the measured hydroxyl value is changed to 104 mg KOH / g; and in the preparation of polyurethane prepolymer in step 3, the amount of polythioketal diol is changed to 14.3 g.

[0055] Embodiment 4:

[0056] The steps are similar to those of Example 1, except that in step 1, in the preparation of polythioketal dithiol, 3,6-dioxa-1,8-octanedithiol (EG2) is changed to bis(2-mercaptoethyl) ether (EG1), and the amount added is adaptively adjusted to 27.65 g (the molar ratio of the feed remains unchanged); in step 2, in the preparation of polythioketal diol, the amount of 2-bromoethanol is changed to 20 g, and the measured hydroxyl value is changed to 57 mgKOH / g; in step 3, in the preparation of the polyurethane prepolymer, the amount of polythioketal diol is changed to 26.1 g.

[0057] Embodiment 5:

[0058] The steps are similar to those of Example 1, except that in step 1, 3,6-dioxa-1,8-octanedithiol (EG2) is replaced by 1,4-butanedithiol (EG0) in the preparation of polythioketal dithiol, and the amount added is adaptively adjusted to 24.45 g (the molar ratio of the feed remains unchanged); in step 2, the amount of 2-bromoethanol in the preparation of polythioketal diol is replaced by 18 g, and the measured hydroxyl value is replaced by 63 mg KOH / g; in step 3, the amount of polythioketal diol in the preparation of the polyurethane prepolymer is replaced by 23.5 g.

[0059] The synthetic routes and H NMR spectra of the three polythioketal diols (EG0 PTK diol, EG1 PTK diol and EG2PTK diol) synthesized in Examples 1, 4 and 5 are as follows: Figure 1 and 2 As shown, the results showed that the polythioketal diol compound was successfully synthesized.

[0060] Embodiment 6:

[0061] The steps are as in Example 1, except that in step 3, no polymethylene polyphenyl polyisocyanate is used, and the amount of diphenylmethane diisocyanate added is changed to 9.24 g.

[0062] Embodiment 7:

[0063] The steps are similar to those of Example 1, except that the mass fraction of the triethylenediamine solution in step 4 is changed to 0.2%.

[0064] Embodiment 8:

[0065] The steps are similar to those of Example 1, except that when preparing component B, 20% by mass of polyethylene glycol 400 is additionally added to the dopamine-modified castor oil.

[0066] Comparative Example 1:

[0067] 1. Preparation of polyurethane prepolymer

[0068] According to R value = 3 (R value is the molar ratio of isocyanate group (-NCO) to hydroxyl group (-OH) in polyurethane), 26.4g of polyethylene glycol 2000 was added to the reactor and the water was thoroughly removed. 1g of polymethylene polyphenyl polyisocyanate and 9g of diphenylmethane diisocyanate were added under nitrogen protection. The prepolymerization was carried out by heating at 80°C under nitrogen protection for 5 hours to obtain a polyurethane prepolymer, which was then dried and sealed at low temperature for storage.

[0069] 2. The preparation process of component B and medical adhesive is the same as that in Example 1.

[0070] Experimental Examples

[0071] (1) In vitro bone bonding experiment

[0072] Before the experiment, the pig cancellous bones were selected and cut into small pieces, and then polished into 5×18×32mm 3 The cuboid is divided into two cuboids of equal volume, with a cross-sectional area of ​​5×18mm 2 After the cross section is polished, wipe the section to be bonded with cotton dipped in the solution, keep the surface to be bonded moist, and evenly apply the prepared polyurethane adhesive. After the two bones are bonded, they are fixed and placed in three different environments. After 24 hours of post-curing, the samples are taken out for bonding performance testing.

[0073] There are three different environments:

[0074] Environment 1, no direct contact with water after bone bonding;

[0075] Environment 2, bone bonding was followed by placement in a cotton ball soaked in PBS buffer solution;

[0076] Environment 3, bone bonding and placement in PBS buffer solution.

[0077] (2) Sample adhesion performance test method

[0078] In vitro bone bonding strength: The in vitro bone bonding strength was measured using an INSTRON 4465 electronic universal testing machine, a stress sensor of 2kN, a tensile rate of 5mm / min, and testing at room temperature.

[0079] Compression strength and compression modulus: tested at room temperature using an INSTRON 4465 electronic universal testing machine, a stress sensor of 2kN, a compression rate of 2mm / min, a compression strain limit of 50%. Sample specifications: The cylinder with h = 13 mm was used to measure the compressive strength and compression modulus of the sample.

[0080] (3) In vitro degradation performance test:

[0081] The adhesive samples obtained in Examples 1-8 and Comparative Example 1 were made into 1×1 cm 2 The slices were weighed and recorded as m. The samples were soaked in a phosphate buffer solution (PBS) with a pH of 7.4 and containing 0.1M hydrogen peroxide. The samples were shaken at 37°C at 100rpm. The samples were taken out at the set time point, freeze-dried and weighed to record the mass as m. At the same time, PBS was replaced with fresh hydrogen peroxide buffer solution. The calculation formula of in vitro degradation rate (Degradation Rate, DR) is as follows:

[0082]

[0083] (4) Cytotoxicity of the extract.

[0084] The cytotoxicity of the adhesive was determined by CCK-8 analysis using L929 cells. 100 mg of the sample was added to 1 mL of culture medium and incubated at 37°C for 1 day. The extract was then diluted 10, 100, and 1000 times with culture medium. The diluted degradation solution of each group was added to 2 × 10 3 The cells were cultured in a 96-well plate with 100 μL of cells / well, and the amount added to each well was 100 μL. They were then placed in a cell culture incubator at 37°C, 5% CO2 for 24 hours and 72 hours, respectively. After culture, the supernatant was aspirated from the well plate, and 20 μL of CCK-8 (5 mg / ml, PBS) solution was added to each well, and then placed in an environment of 37°C for 4 hours. The absorbance (OD value) of each well was measured using an ELISA reader (450 nm). Cell viability was quantified by the following formula:

[0085]

[0086] Controls were cells incubated with culture medium.

[0087] When the cell viability was higher than 75%, it was considered as cytotoxicity.

[0088] The test results are shown in Table 1 below.

[0089] Table 1

[0090]

[0091] It can be seen from Examples 1-3 that the smaller the molar ratio of the ketal compound M to the thiol compound N, the shorter the degradation time of the obtained medical adhesive. This may be because the decrease in the molar ratio of the two leads to a decrease in the degree of polymerization of the synthesized polythioketal dithiol, thereby reducing the density of degradation sites.

[0092] It can be seen from Examples 1, 4 and 5 that as the ethylene glycol structural unit in the polythioketal diol decreases, the hydrophilicity of the medical adhesive decreases, the wettability with the degradation liquid decreases, and the degradation time of the obtained medical adhesive becomes longer.

[0093] It can be seen from Examples 1 and 6 that when polymethylene polyphenyl polyisocyanate is not used, the compression properties and bonding properties of the obtained medical adhesive are reduced, which may be because the decrease in crosslinking density reduces the cohesive strength.

[0094] It can be seen from Examples 1 and 7 that increasing the concentration of the catalyst will accelerate the curing of the medical adhesive.

[0095] It can be seen from Examples 1 and 8 that the addition of polyethylene glycol to component B will accelerate the degradation of the medical adhesive, but the mechanical properties will be lost to a certain extent.

[0096] It can be seen from Examples 1-8 that the medical adhesive for bone trauma repair obtained by the present invention has high bonding strength and controllable degradation performance, and has great potential in bone trauma repair.

[0097] However, due to the lack of degradable groups, the degradation time of Control Example 1 is too long and cannot meet clinical requirements.

[0098] The above contents are further detailed descriptions of the present invention in combination with specific implementation methods, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the scope of protection of the present invention.

Claims

1. A medical adhesive for bone trauma repair, comprising component A and component B, wherein component A is an isocyanate-terminated polyurethane prepolymer, and component B comprises dopamine-modified castor oil polyol, inorganic particles, a catalyst and a foaming agent, wherein: The molar ratio of -NCO groups in the isocyanate-terminated polyurethane prepolymer to -OH groups in the dopamine-modified castor oil polyol is (0.8-1.2):

1.

2. The medical adhesive according to claim 1, wherein The isocyanate-terminated polyurethane prepolymer is prepared by the following method: The first step: firstly, the ketal compound M reacts with the thiol compound N to generate the sulfur-containing ketal monomer O; Step 2: The halogenated alcohol is reacted with the sulfur-containing ketal monomer O to obtain the polythioketal polyol P; Step 3: Finally, the isocyanate-terminated polyurethane prepolymer is obtained by reacting the polythioacetal polyol P with the isocyanate-containing compound U, wherein the molar ratio of the -NCO group in the isocyanate-containing compound U to the -OH group in the polythioacetal polyol P is (0.8-1.2):

1.

3. The medical adhesive according to claim 2, wherein: The ketal compound M is 2,2-dimethoxypropane; the thiol compound N is selected from 3,6-dioxa-1,8-octanedithiol, bis(2-mercaptoethyl) ether and 1,4-butanedithiol.

4. The medical adhesive according to claim 2, wherein: The molar ratio of the ketal compound M to the thiol compound N is in the range of (1-2):

1.

5. The medical adhesive according to claim 2, wherein: The isocyanate-containing compound U is selected from diisocyanates and polyisocyanates. The diisocyanate includes one or more of diphenylmethane diisocyanate, toluene diisocyanate, p-phenylene diisocyanate, m-xylylene diisocyanate, tetramethylm-xylylene diisocyanate, dimethylbiphenyl diisocyanate, and dimethyldiphenylmethane diisocyanate; the polyisocyanate is selected from one or more of polymethylene polyphenyl polyisocyanate, triphenylmethane triisocyanate, and dimethyltriphenylmethane tetraisocyanate.

6. The medical adhesive according to claim 1, wherein: The B component is prepared by the following method: The first step: firstly grafting succinic anhydride onto castor oil, castor oil polyol or modified castor oil polyol through condensation reaction; Step 2: preparing dopamine-modified castor oil polyol through amidation reaction with dopamine; Step 3: Mixing the dopamine-modified castor oil polyol with inorganic particles, a catalyst and a foaming agent to obtain component B.

7. The medical adhesive according to claim 6, wherein: The catalyst is an amine catalyst, and the amine catalyst is selected from one or more of 1,2-dimethylimidazole, triethylenediamine, pentamethyldiethylenetriamine, and pentamethyldipropylenetriamine.

8. The medical adhesive according to claim 1, wherein The molecules of the A component contain The structure is as follows, wherein n is any integer from 1 to 100; the B component contains polyethylene glycol, and the number average molecular weight thereof is in the range of 100 to 10000.

9. The medical adhesive according to claim 1, wherein: The inorganic particles are one or more of α-tricalcium phosphate, β-tricalcium phosphate, calcium carbonate, hydroxyapatite, and biphasic calcium phosphate.

10. The method for preparing the medical adhesive according to any one of claims 1 to 9, comprising mixing component A and component B through a mixing syringe at a functional group molar ratio of -NCO:-OH=(0.8-1.2):1.